Single Arm Romiplostim to Prevent CIT

Exclusion Criteria

• •Concomitant therapy, non-cancer directed:
• •* Previous use of romiplostim, eltrombopag or any other platelet-producing agent is not allowed.
• •* Previous therapy for immune thrombocytopenia and related conditions, including rituximab, mycophenolic acid, protracted systemic steroids, and/or IVIG, is prohibited.
• •* Treatment with erythropoietin-stimulating agents is prohibited.
• •* Patients who are receiving prophylactic dosing of heparin (i.e. enoxaparin) or oral anticoagulants (i.e. rivaroxaban) for thrombosis prevention may be considered for enrollment but will be excluded from secondary aim 'a' analysis (efficacy measured as the median platelet count and transfusion dependency) given shift in transfusion thresholds.